Loss of SDHB Induces a Metabolic Switch in the hPheo1 Cell Line toward Enhanced OXPHOS

Mouna Tabebi1, Ravi Kumar Dutta1, Camilla Skoglund1

  • 1Department of Biomedical and Clinical Sciences (BKV), Linköping University, 581 83 Linköping, Sweden.

Abstract

Insights

Succinate dehydrogenase B (SDHB) mutations in pheochromocytomas and paragangliomas (PCCs/PGLs) increase GLUD1 expression. This suggests GLUD1 may be a therapeutic target for SDHB-deficient tumors.

Area of Science:

  • Biochemistry
  • Oncology
  • Molecular Biology

Background:

  • Tricarboxylic acid (TCA) cycle enzymes are emerging tumor suppressors.
  • Mutations in succinate dehydrogenase B (SDHB) are linked to pheochromocytomas/paragangliomas (PCCs/PGLs) and poor prognosis.

Purpose of the Study:

  • To investigate the molecular consequences of SDHB downregulation in PCCs/PGLs.
  • To identify potential biomarkers and therapeutic targets in SDHB-deficient tumors.

Main Methods:

  • CRISPR-cas9 technology was used to knock down SDHB gene expression in the hPheo1 human pheochromocytoma cell line.
  • Microarray gene expression analysis and TCGA data analysis were performed.

Main Results:

  • SDHB knockdown upregulated genes involved in glycolysis, hypoxia, and proliferation, while downregulating oxidative phosphorylation (OXPHOS) genes.
  • Cells adapted by utilizing glutamine for energy and promoting OXPHOS.
  • SDHB knockdown significantly increased GLUD1 expression, confirmed in TCGA data for SDHB-mutated PCCs/PGLs.

Conclusions:

  • Downregulation of SDHB in PCCs/PGLs leads to increased GLUD1 expression.
  • GLUD1 represents a potential biomarker and therapeutic target for SDHB-mutated tumors and diseases with SDHB loss of activity.